The Mouse Defense Test Battery: Pharmacological and behavioral assays for anxiety and panic

European Journal of Pharmacology

Volumn 463, Issue 1-3, 2003, Pages 97-116

  Blanchard, D Caroline ^a,b   Griebel, Guy ^c   Blanchard, Robert J ^d  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c SANOFI   (France)

^d NONE

Author keywords

5 HT (5 hydroxytryptamine, serotonin); Anxiety; GABAA benzodiazepine receptor; Mouse Defense Test Battery; Neuropeptide; Panic

Indexed keywords

1 [5 CHLORO 1 (2,4 DIMETHOXYLPHENYLSULFONYL) 2,3 DIHYDRO 3 (2 METHOXYPHENYL) 2 OXO 1H INDOL 3 YL] 4 HYDROXY N,N DIMETHYL 2 PYRROLIDINECARBOXAMIDE; 1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 2 (4 CHLOROPHENYL) 5,6 DIHYDRO [1]BENZOTHIEPINO[5,4 C]PYRIDAZIN 3(2H) ONE 7 OXIDE; 2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 2 [[1 (7 CHLORO 4 QUINOLINYL) 5 (2,6 DIMETHOXYPHENYL) 3 PYRAZOLYL]CARBONYLAMINO] 2 ADAMANTANECARBOXYLIC ACID; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 METHYL 6 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 TRIAZOLO[4,3 B]PYRIDAZINE; 3 [1 [2 [4 BENZOYL 2 (3,4 DIFLUOROPHENYL) 2 MORPHOLINYL]ETHYL] 4 PHENYL 4 PIPERIDINYL] 1,1 DIMETHYLUREA; 3 [2 [4 (4 FLUOROBENZOYL)PIPERIDINO]ETHYL] 6 [4 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]BUTYL]BENZOTHIAZOLIN 2 ONE; 6 FLUORO 2,9 DIHYDRO 9 METHYL 2 PHENYL 4 (1 PYRROLIDINYLCARBONYL) 1H PYRIDO[3,4 B]INDOL 1 ONE; ABECARNIL; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ALPRAZOLAM; ANTIPANIC AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA CARBOLINE 3 CARBOXYLIC ACID; BRETAZENIL; BUSPIRONE; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CHLORDIAZEPOXIDE; CLOBAZAM; CLONAZEPAM; CLORAZEPATE; DIAZEPAM; FLAVONE DERIVATIVE; GEPIRONE; GR 159897; IMIDAZENIL; LIGAND; N (4 BROMOPHENYL) 3 OXO 4,5 DIPHENYL 1 PYRAZOLIDINECARBOXAMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROPEPTIDE; PD 135 158; PD 171 729; RO 194603; RO 198022; RWJ 46771; S 21187; SAREDUTANT; SEROTONIN; SL 88 0338; SX 3228; TRIAZOLAM; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALEPLON; ZOLPIDEM; ZOPICLONE;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; COGNITION; CONTROLLED STUDY; DEFENSIVE BEHAVIOR; EMOTION; FACTORIAL ANALYSIS; FLIGHT; FREEZING; MOUSE; NONHUMAN; PANIC; PRIORITY JOURNAL; RAT; RISK ASSESSMENT;

EID: 0037470186     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01276-7     Document Type: Article

References (186)

1. Aguilera G., Rabadan-Diehl C. Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation. Regulatory Pept. 96:2000;23-29.
2. Anton B., Fein J., To T., Li X., Silberstein L., Evans C.J. Immunohistochemical localization of ORL-1 in the central nervous system of the rat. J. Comp. Neurol. 368:1996;229-251.
3. Apter J.T., Allen L.A. Buspirone: future directions. J. Clin. Psychopharmacol. 19:1999;86-93.
4. Ashok Raj B., Sheehan D.V. Somatic treatment strategies in panic disorder. Asnis G.M., Van Praag H.M. Panic Disorder. Clinical, Biological, and Treatment Aspects. 1995;279-313 Wiley, New York.
5. Barradell L.B., Fitton A. Tandospirone. CNS Drugs. 5:1996;147-153.
6. Bell C.J., Nutt D.J. Serotonin and panic. Br. J. Psychiatry. 172:1998;465-471.
7. Belzung C., Misslin R., Vogel E. Anxiogenic effects of a benzodiazepine receptor partial inverse agonist, RO 19-4603, in a light/dark choice situation. Pharmacol. Biochem. Behav. 36:1990;593-596.
8. Belzung C., Leguisquet A.M., Crestani F. Flumazenil induces benzodiazepine partial agonist-like effects in BALB/c but not C57BL/6 mice. Psychopharmacology. 148:2000;24-32.
9. Betancur C., Azzi M., Rostene W. Nonpeptide antagonists of neuropeptide receptors: tools for research and therapy. Trends Pharmacol. Sci. 18:1997;372-386.
10. Billett E.A., Richter M.A., King N., Heils A., Lesch K.P., Kennedy J.L. Obsessive compulsive disorder, response to serotonin reuptake inhibitors and the serotonin transporter gene. Mol. Psychiatry. 2:1997;403-406.
11. Blanchard D.C. Stimulus and environmental control of defensive behaviors. Bouton M., Fanselow M. The Functional Behaviorism of Robert C. Bolles: Learning, Motivation and Cognition. 1997;283-305 American Psychological Association, Washington, DC.
12. Blanchard R.J., Blanchard D.C. Effects of hippocampal lesions on the rat's reaction to a cat. J. Comp. Physiol. Psychol. 78:1972;77-82.
13. Blanchard R.J., Blanchard D.C. Anti-predator defensive behaviors in a visible burrow system. J. Comp. Psychol. 103:1989;70-82.
14. 1A agonists buspirone and gepirone. Pharmacol. Biochem. Behav. 31:1988;269-278.
15. Blanchard D.C., Rodgers R.J., Hori K., Hendrie C.A., Blanchard R.J. Attenuation of defensive threat and attack in wild rats (Rattus rattus) by benzodiazepines. Psychopharmacology. 97:1989;392-401.
16. 1A agonists and benzodiazepines on defensive patterns in wild Rattus rattus. Bevan P., Cools A.R., Archer T. Behavioral Pharmacology of 5-HT. 1989;145-149 Lawrence Earlbaum, New York, NY.
17. Blanchard D.C., Blanchard R.J., Tom P., Rodgers R.J. Diazepam alters risk assessment in an anxiety/defense test battery. Psychopharmacology. 101:1990;511-518.
18. Blanchard D.C., Blanchard R.J., Rodgers R.J. Pharmacological and neural control of anti-predator defense in the rat. Aggress. Behav. 16:1990;165-176.
19. Blanchard D.C., Blanchard R.J., Rodgers R.J. Risk assessment and animal models of anxiety. Olivier B., Mos J., Slangen J.L. Animal Models in Psychopharmacology. 1991;117-134 Birkhäuser Verlag, Basel.
20. Blanchard D.C., Weatherspoon A., Shepard J.K., Rodgers R.J., Blanchard R.J. "Paradoxical" effects of morphine on anti-predator defense reactions in wild and laboratory (R. norvegicus) rats. Pharmacol. Biochem. Behav. 40:1991;819-828.
21. Blanchard D.C., Shepherd J.K., Rodgers R.J., Blanchard R.J. Evidence for differential effects of 8-OH-DPAT on male and female rats in the Anxiety/Defense Test Battery. Psychopharmacology. 106:1992;531-539.
22. Blanchard D.C., Shepard J.K., Rodgers R.J., Blanchard R.J. Attenuation for antipredator defensive behavior following chronic treatment with the tricyclic antidepressant, imipramine. Psychopharmacology. 110:1993;245-253.
23. Blanchard R.J., Yudko E.B., Rodgers R.J., Blanchard D.C. Defense system psychopharmacology: an ethological approach to the pharmacology of fear and anxiety. Behav. Brain Res. 58:1993;155-165.
24. Blanchard R.J., Parmigiani S., Agullana R., Weiss S.M., Blanchard D.C. Behaviors of Swiss-Webster and C57 mice in a Fear/Defense Test Battery. Aggress. Behav. 21:1995;21-28.
25. Blanchard R.J., Parmigiani S., Bjornson D., Masuda C., Weiss S.M., Blanchard D.C. Antipredator behavior of Swiss-Webster mice in a Visible Burrow System. Aggress. Behav. 21:1995;123-136.
26. Blanchard R.J., Griebel G., Guardiola-Lemaitre B., Brush M.M., Lee J., Blanchard D.C. An ethopharmacological analysis of selective activation of 5-HT1A receptors: the mouse 5-HT1A syndrome. Pharmacol. Biochem. Behav. 57:1997;897-908.
27. Blanchard R.J., Griebel G., Henrie J.A., Blanchard D.C. Differentiation of anxiolytic and panicolytic drugs by effects on rat and mouse defense test batteries. Neurosci. Biobehav. Rev. 21:1997;783-789.
28. Blanchard D.C., Griebel G., Blanchard R.J. Mouse defensive behaviors: pharmacological and behavioral assays for anxiety and panic. Neurosci. Biobehav. Rev. 25:2001;205-218.
29. Bradwejn J., Koszycki D., Couëtoux du Tertre A., Van Megen H., Den Boer J., Westenberg H., Annable L. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch. Gen. Psychiatry. 51:1994;486-493.
30. Bradwejn J., Koszycki D., Paradis M., Reece P., Hinton J., Sedman A. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. Biol. Psychiatry. 38:1995;742-746.
31. Broocks A., Pigott T.A., Hill J.L., Canter S., Grady T.A., L'Heureux F., Murphy D.L. Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results. Psychiatry Res. 79(1):1998;11-20.
32. Buller R. Reversible inhibitors of monoamine oxidase A in anxiety disorders. Clin. Neuropharmacol. 18:1995;S38-S44.
33. Calo G., Bigoni R., Rizzi A., Guerrini R., Salvadori S., Regoli D. Nociceptin/orphanin FQ receptor ligands. Peptides. 21:2000;935-947.
34. Calo G., Guerrini R., Rizzi A., Salvadori S., Regoli D. Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br. J. Pharmacol. 129:2000;1261-1283.
35. 1A receptor antagonist, in the murine elevated plus-maze. Psychopharmacology. 129:1997;365-371.
36. Cao B.J., Rodgers R.J. Influence of 5-HT1A receptor antagonism on plus-maze behaviour in mice: 1. Pindolol enantiomers and pindobind 5-HT1A. Pharmacol. Biochem. Behav. 58:1997;583-591.
37. 1A receptor antagonism on plus-maze behaviour in mice: II. WAY 100635, SDZ 216-525 and NAN-190. Pharmacol. Biochem. Behav. 58:1997;593-603.
38. Ceulemans D.L., Hoppenbrouwers M.L., Gelders Y.G., Reyntjens A.J. The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam. Pharmacopsychiatry. 18:1985;303-305.
39. 1 receptor mRNA expression. J. Neurosci. 15:1995;6340-6350.
40. Chalmers D.T., Lovenberg T.W., Grigoriadis D.E., Behan D.P., De Souza E.B. Corticotrophin-releasing factor receptors: from molecular biology to drug design. Trends Pharmacol. Sci. 17:1996;166-172.
41. Ciccocioppo R., Martin-Fardon R., Weiss F., Massi M. Nociceptin/orphanin FQ inhibits stress- and CRF-induced anorexia in rats. NeuroReport. 12:2001;1145-1149.
42. Cutler N.R., Sramek J.J., Keppel Hesselink J.M., Krol A., Roeschen J., Rickels K., Schweizer E. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial. J. Clin. Psychopharmacol. 13:1993;429-437.
43. Darragh A., Lambe R., O'Boyle C., Kenny M., Brick I. Absence of central effects in man of the benzodiazepine antagonist Ro 15-1788. Psychopharmacology. 80:1983;192-195.
44. Deakin J.F.W., Graeff F.G. 5-HT and mechanisms of defense. J. Psychopharmacol. 5:1991;305-315.
45. De Catanzaro D. Effect of predator exposure upon early pregnancy in mice. Physiol. Behav. 43:1988;691-696.
46. Den Boer J.A., Westenberg H.G. Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology. 102:1990;85-94.
47. Den Boer J.A., Westenberg H.G., De Leeuw A.S., van Viliet I.M. Biological dissection of anxiety disorders: the clinical role of selective serotonin reuptake inhibitors with particular reference to fluvoxamine. Int. Clin. Psychopharmacol. 4:1995;47-52.
48. Depoortere H., Zivkovic B., Lloyd K.G., Sanger D.J., Perrault G., Langer S.Z., Bartholini G. Zolpidem, a novel non-benzodiazepine hypnotic: I. Neuropharmacological and behavioral effects. J. Pharmacol. Exp. Ther. 237:1986;649-658.
49. De Vries G.J., Buijs R.M. The origin of the vasopressinergic and oxytocinergic innervation of the rat brain with special reference to the lateral septum. Brain Res. 273:1983;307-317.
50. De Weerth A., Pisegna J.R., Huppi K., Wank S.A. Molecular cloning, functional expression and chromosomal localization of the human cholecystokinin type A receptor. Biochem. Biophys. Res. Commun. 194:1993;811-818.
51. DSM-IV Diagnostic and Statistical Manual of Mental Disorders. 4th ed. 1994;American Psychiatric Association, Washington, DC.
52. Duka T., Ackenheil M., Noderer J., Doenicke A. Changes in noradrenaline plasma levels and behavioural responses induced by benzodiazepine agonists with the benzodiazepine antagonist Ro 15-1788. Psychopharmacology. 90:1986;351-357.
53. Dunlop J. CCK receptor antagonists. Gen. Pharmacol. 31:1998;519-524.
54. Edmunds M. Defence in Animals. 1974;Longman, New York.
55. Eisenberg J.F. The Mammalian Radiations: An Analysis of Trends in Evolution, Adaptation, and Behavior. 1981;University of Chicago Press, Chicago.
56. Eison A.S., Eison M.S. Serotonergic mechanisms in anxiety. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 18(1):1994;47-62.
57. Elde R., Schalling M., Ceccatelli S., Nakanishi S., Hokfelt T. Localization of neuropeptide receptor mRNA in rat brain: initial observations using probes for neurotensin and substance P receptors. Neurosci. Lett. 120:1990;134-138.
58. Endler J.A. Defense against predators. Feder M.E., Lauder G.V. Predator-Prey Relationships. 1986;109-134 University of Chicago Press, Chicago.
59. Estes W.K., Skinner B.F. Some quantitative properties of anxiety. J. Exp. Psychol. 29:1941;390-400.
60. Fichtner C.G., Poddig B.E., deVito R.A. Post-traumatic stress disorder: pathophysiological aspects and pharmacological approaches to treatment. CNS Drugs. 8:1997;293-322.
61. Freud S. Inhibitions, Symptoms, and Anxiety. 1930;Hogarth Press, London.
62. Fulton B., Brogden R.N. Buspirone: an updated review of its clinical pharmacology and therapeutic applications. CNS Drugs. 7:1997;68-88.
63. Garakani H., Zitrin C.M., Klein D.F. Treatment of panic disorder with imipramine alone. Am. J. Psychiatry. 141:1984;446-448.
64. A receptors. J. Pharmacol. Exp. Ther. 266:1993;1018-1028.
65. Graeff F.G. Brain defense system and anxiety. Burrows G.D., Roth M., Noyes R. Jr. Handbook of Anxiety. The Neurobiology of Anxiety. vol. 3:1990;307-343 Elsevier, Amsterdam.
66. 3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting: a comparison of their pharmacology and clinical efficacy. Drug. 55(2):1998;173-189.
67. Griebel G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol. Ther. 65:1995;319-395.
68. Griebel G. Serotonergic drugs in animal models of anxiety: an update. Serotonin ID Res. Alert. 2:1997;251-257.
69. 1A receptor blockers as potential drug candidates for the treatment of anxiety disorders. Drug News Perspect. 12:1999;484-490.
70. Griebel G. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol. Ther. 82:1999;1-61.
71. Griebel G., Blanchard D.C., Agnes R.S., Blanchard R.J. Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine. Psychopharmacology. 120:1995;57-66.
72. Griebel G., Blanchard D.C., Jung A., Blanchard R.J. A model of 'antipredator' defense in Swiss-Webster mice: effects of benzodiazepine receptor ligands with different intrinsic activities. Behav. Pharmacol. 6:1995;732-745.
73. Griebel G., Blanchard D.C., Jung A., Lee J.C., Masuda C.K., Blanchard R.J. Further evidence that the Mouse Defense Test Battery is useful for screening anxiolytic and panicolytic drugs: effects of acute and chronic treatment with alprazolam. Neuropharmacology. 34:1995;1625-1633.
74. 2A antagonist pirenperone. Pharmacol. Biochem. Behav. 51:1995;235-244.
75. Griebel G., Blanchard D.C., Blanchard R.J. Evidence that the behaviors in the Mouse Defense Test Battery relate to different emotional states: a factor analytic study. Physiol. Behav. 60:1996;1255-1260.
76. Griebel G., Blanchard D.C., Blanchard R.J. Predator-elicited flight responses in Swiss-Webster mice: an experimental model of panic attacks. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 20:1996;185-205.
77. 2A receptor antagonist S21357. Pharmacol. Biochem. Behav. 54:1996;509-516.
78. Griebel G., Sanger D.J., Perrault G. The Mouse Defense Test Battery: evaluation of the effects of non-selective and BZ-1 (ω1) selective, benzodiazepine receptor ligands. Behav. Pharmacol. 7:1996;560-572.
79. Griebel G., Perrault G., Sanger D.J. A comparative study of the effects of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety. Neuropharmacology. 36:1997;793-802.
80. Griebel G., Perrault G., Sanger D.J. Behavioural profiles of the reversible monoamine-oxidase-A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs. Psychopharmacology. 131:1997;180-186.
81. Griebel G., Perrault G., Sanger D.J. CCK receptor antagonists in animal models of anxiety: comparison between exploration tests, conflict procedures and a model based on defensive behaviours. Behav. Pharmacol. 8:1997;549-560.
82. Griebel G., Curet O., Perrault G., Sanger D.J. Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs: correlation with changes in monoamine-oxidase activity and monoamine levels. Neuropharmacology. 37:1998;927-935.
83. Griebel G., Perrault G., Sanger D.J. Characterization of the behavioral profile of the non peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents - comparison with diazepam and buspirone. Psychopharmacology. 138:1998;55-66.
84. Griebel G., Perrault G., Sanger D.J. Limited anxiolytic-like effects of non-benzodiazepine hypnotics in rodents. J. Psychopharmacol. 12:1998;356-365.
85. Griebel G., Perrault G., Sanger D.J. Differences in anxiolytic-like profile of two novel nonbenzodiazepine BZ (ω) receptor agonists on defensive behaviors of mice. Pharmacol. Biochem. Behav. 62:1999;689-694.
86. Griebel G., Perrault G., Sanger D.J. Orphanin FQ, a novel neuropeptide with anti-stress-like activity. Brain Res. 836:1999;221-224.
87. Griebel G., Perrault G., Tan S., Schoemaker H., Sanger D.J. Pharmacological studies on synthetic flavonoids: comparison with diazepam. Neuropharmacology. 38:1999;965-977.
88. 1A receptor antagonists. Psychopharmacology. 144:1999;121-130.
89. Griebel G., Perrault G., Sanger D.J. Subtype-selective benzodiazepine receptor ligands. Briley M., Nutt D. Anxiolytics. 2000;77-94 Birkhäuser, Basel.
90. Griebel G., Rodgers R.J., Perrault G., Sanger D.J. The effects of compounds varying in selectivity as 5-HT1A receptor antagonists in three rat models of anxiety. Neuropharmacology. 39:2000;1848-1857.
91. Griebel G., Moindrot N., Aliaga C., Simiand J., Soubrie P. Characterization of the profile of neurokinin-2 and neurotensin receptor antagonists in the mouse defense test battery. Neurosci. Biobehav. Rev. 25:2001;619-626.
92. A) receptors. J. Pharmacol. Exp. Ther. 298:2001;753-768.
93. Griebel G., Perrault G., Soubrie P. Effects of SR48968, a selective non-peptide NK2 receptor antagonist on emotional processes in rodents. Psychopharmacology. 158:2001;241-251.
94. Griebel G., Simiand J., Serradeil-Le Gal C., Wagnon J., Pascal M., Scatton B., Maffrand J.-P., Soubrié P. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc. Natl. Acad. Sci. U. S. A. 99:2002;6370-6375.
95. 1 receptor antagonist: II. Characterization in rodent models of stress-related disorders. J. Pharmacol. Exp. Ther. 301:2002;333-345.
96. Gudelsky G.A., Berry S.A., Meltzer H.Y. Neurotensin activates tuberoinfundibular dopamine neurons and increases serum corticosterone concentrations in the rat. Neuroendocrinology. 49:1989;604-609.
97. Gully D., Canton M., Boigegrain R., Jeanjean F., Molimard J.C., Poncelet M., Gueudet C., Heaulme M., Leyris R., Brouard A., Pelaprat D., Labbé-Jullié C., Mazella J., Soubrié P., Maffrand J.P., Rostène W., Kitabgi P., Le Fur G. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc. Natl. Acad. Sci. U. S. A. 90:1993;65-69.
98. Gutman D.A., Owens M.J., Nemeroff C.B. Corticotropin-releasing factor antagonists as novel psychotherapeutics. Drugs Future. 25:2000;923-931.
99. Haefely W., Martin J.R., Schoch P. Novel anxiolytics that acts as partial agonists at benzodiazepine receptors. Trends Pharmacol. Sci. 11:1990;452-456.
100. Helmreich D.L., Watkins L.R., Deak T., Maier S.F., Akil H., Watson S.J. The effect of stressor controllability on stress-induced neuropeptide mRNA expression within the paraventricular nucleus of the hypothalamus. J. Neuroendocrinol. 11:1999;121-128.
101. Hokfelt T., Skirboll L., Everitt B., Meister B., Brownstein M., Jacobs T., Faden A., Kuga S., Goldstein M., Markstein R. Distribution of cholecystokinin-like immunoreactivity in the nervous system. Co-existence with classical neurotransmitters and other neuropeptides. Ann. N.Y. Acad. Sci. 448:1985;255-274.
102. Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J. Psychiat. Res. 33:1999;181-214.
103. Humble M., Asberg-Wistedt A., Wistedt B., Bertilsson L. A pilot study of ritanserin (a selective serotonin-2 receptor antagonist) in panic disorder and agoraphobia. Clinical and biochemical effects. C.I.N.P. Congress, Puerto Rico. 1986;165.
104. Jacobson A.F., Dominguez R.A., Goldstein B.J., Steinbook R.M. Comparison of buspirone and diazepam in generalized anxiety disorder. Pharmacotherapy. 5:1985;290-296.
105. Jenck F., Moreau J.L., Martin J.R., Kilpatrick G.J., Reinscheid R.K., Monsma F.J., Nothacker H.P., Civelli O. Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress. Proc. Natl. Acad. Sci. U. S. A. 94:1997;14854-14858.
106. Jenck F., Ouagazzal A.M., Pauly Evers M., Moreau J.L. Orphanin FQ: role in behavioral fear responses and vulnerability to stress? Mol. Psychiatry. 5:2000;572-574.
107. Kay B., Healy T.E. Premedication by controlled-release morphine. Anaesthesia. 39(6):1984;587-589.
108. King S.M. Escape-related behaviours in an unstable elevated and exposed environment: I. A new behavioural model of extreme anxiety. Behav. Brain Res. 98:1999;113-126.
109. Klusha V.E., Mutsenietse R.K., Svirskis S.V., Zalitis G.M., Liepa I.R. Neuroimmunoregulatory properties of short protein fragments in rats exposed to immobilization stress. Bull. Eksp. Biol. Med. 104:1987;186-187.
110. Köster A., Montkowski A., Schulz S., Stube E.M., Knaudt K., Jenck F., Moreau J.L., Nothacker H.P., Civelli O., Reinscheid R.K. Targeted disruption of the orphanin FQ/nociceptin gene increases stress susceptibility and impairs stress adaptation in mice. Proc. Natl. Acad. Sci. U. S. A. 96:1999;10444-10449.
111. B antagonist, in panic disorder. Biol. Psychiatry. 37:1995;462-466.
112. Lader M. Benzodiazepines: a risk-benefit profile. CNS Drugs. 1:1994;377-387.
113. Leyhausen P. Cat Behavior: The Predatory and Social Behavior of Domestic and Wild Cats. 1969;Garland STPM Press, New York. 1979.
114. Liao N., Bulant M., Nicholas P., Vaudry H., Pelletier G. Immunocytochemical distribution of neurons containing a peptide derived from thyrotropin-releasing hormone precursor in the rat brain. Neurosci. Lett. 85:1988;24-28.
115. Liebowitz M.R., Hollander E., Schneier F., Campeas R., Welkowitz L., Hatterer J., Fallon B. Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders. Acta Psychiatr. Scand., Suppl. 360:1990;29-34.
116. Lines C., Challenor J., Traub M. Cholecystokinin and anxiety in normal volunteers: an investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype B antagonist L-365,260. Br. J. Clin. Pharmacol. 39:1995;235-242.
117. Lolait S.J., O'Carroll A.M., Mahan L.C., Felder C.C., Button D.C., Young W.S. III, Mezey E., Brownstein M.J. Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc. Natl. Acad. Sci. U. S. A. 92:1995;6783-6787.
118. Low K., Crestani F., Keist R., Benke D., Brunig I., Benson J.A., Fritschy J.M., Rulicke T., Bluethmann H., Mohler H., Rudolph U. Molecular and neuronal substrate for the selective attenuation of anxiety. Science. 290:2000;131-134.
119. Maddock R.J. Acute effects of low-dose flumazenil in panic disorder. J. Clin. Psychopharmacol. 18:1998;258-261.
120. Maggi C.A. The mammalian tachykinin receptors. Gen. Pharmacol. 26:1995;911-944.
121. Martin J.R., Pieri L., Bonetti E.P., Schaffner R., Burkard W.P., Cumin R., Haefely W.E. Ro 16-6028: a novel anxiolytic acting as a partial agonist at the benzodiazepine receptor. Pharmacopsychiatry. 21:1988;360-362.
122. McCann S.M., Vijayan E., Koenig J., Krulich L. The effects of neurotensin on anterior pituitary hormone secretion. Ann. N.Y. Acad. Sci. 400:1982;160-171.
123. McCarthy J.R., Heinrichs S.C., Grigoriadis D.E. Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications. Curr. Pharm. Des. 5:1999;289-315.
124. McGivern R.F., Rittenhouse P., Aird F., Van de Kar L.D., Redei E. Inhibition of stress-induced neuroendocrine and behavioral response in the rat by prepro-thyrotropin-releasing hormone 178-199. J. Neurosci. 17:1997;4886-4894.
125. McLeod D.R., Hoehn-Saric R., Porges S.W., Kowalski P.A., Clark C.M. Therapeutic effects of imipramine are counteracted by its metabolite, desipramine, in patients with generalized anxiety disorder. J. Clin. Psychopharmacol. 20(6):2000;615-621.
126. Meunier J.C., Mollereau C., Toll L., Suaudeau C., Moisand C., Alvinerie P., Butour J.L., Guillemot J.C., Ferrara P., Monsarrat B. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor (see comments). Nature. 377:1995;532-535.
127. Modigh K. Antidepressant drugs in anxiety disorders. Acta Psychiatr. Scand., Suppl. 335:1987;57-74.
128. Moran T.H., Robinson P.H., Goldrich M.S., McHugh P.R. Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res. 362:1986;175-179.
129. Morel A., O'Carroll A.M., Brownstein M.J., Lolait S.J. Molecular cloning and expression of a rat V1a arginine vasopressin receptor. Nature. 356:1992;523-526.
130. Nader M.A., Barrett J.E. Effects of corticotropin-releasing factor (CRF), tuftsin and dermorphin on behavior of squirrel monkeys maintained by different events. Peptides. 10:1989;1199-1204.
131. Nemeroff C.B., Luttinger D., Hernandez D.E., Mailman R.B., Mason G.A., Davis S.D., Widerlov E., Frye G.D., Kilts C.A., Beaumont K., Breese G.R., Prange A.J. Jr. Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies. J. Pharmacol. Exp. Ther. 225:1983;337-345.
132. Nicot A., Berod A., Gully D., Rowe W., Quirion R., De Kloet E.R., Rostene W. Blockade of neurotensin binding in the rat hypothalamus and of the central action of neurotensin on the hypothalamic-pituitary-adrenal axis with non-peptide receptor antagonists. Neuroendocrinology. 59:1994;572-578.
133. Nicot A., Rowe W.B., De Kloet E.R., Betancur C., Jessop D.S., Lightman S.L., Quirion R., Rostene W., Berod A. Endogenous neurotensin regulates hypothalamic-pituitary-adrenal axis activity and peptidergic neurons in the rat hypothalamic paraventricular nucleus. J. Neuroendocrinol. 9:1997;263-269.
134. Nikulina E.M. Neural control of predatory aggression in wild and domesticated animals. Neurosci. Biobehav. Rev. 15:1991;545-547.
135. Nutt D.J., Glue P., Lawson C., Wilson S. Flumazenil provocation of panic attacks: evidence for altered benzodiazepine receptor sensitivity in panic disorder. Arch. Gen. Psychiatry. 47:1990;917-925.
136. Otsuka M., Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiol. Rev. 73:1993;229-308.
137. Pande A.C. Lack of efficacy of a cholecystokinin-B antagonist in anxiety disorders. Biol. Psychiatry. 42:1997;11-19.
138. Pecknold J.C., Luthe L., Scott Fleury M.H., Jenkins S. Gepirone and the treatment of panic disorder: an open study. J. Clin. Psychopharmacol. 13:1993;145-149.
139. Pinel J.P.J., Mana M.J. Adaptive interactions of rats with dangerous inanimate objects: support for a cognitive theory of defensive behavior. Blanchard R.J., Brain P.F., Blanchard D.C., Parmigiani S. Ethoexperimental Approaches to the Study of Behavior. 1989;137-151 Kluwer Academic Publishers, Dordrecht.
140. Pisegna J.R., de Weerth A., Huppi K., Wank S.A. Molecular cloning of the human brain and gastric cholecystokinin receptor: structure, functional expression and chromosomal localization. Biochem. Biophys. Res. Commun. 189:1992;296-303.
141. Plata Salaman C.R. Immunoregulators in the nervous system. Neurosci. Biobehav. Rev. 15:1991;185-215.
142. Pohl R., Balon R., Yeragani V.K., Gershon S. Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone. Psychopathology. 22(Suppl. 1):1989;60-67.
143. Pollack M.H., Rosenbaum J.F. Benzodiazepines in panic-related disorders. Special issue: perspectives on panic-related disorders. J. Anxiety Disord. 2:1988;95-107.
144. Potokar J., Nutt D.J. Anxiolytic potential of benzodiazepine receptor partial agonists. CNS Drugs. 1:1994;305-315.
145. Priest R.G., Gimbrett R., Roberts W., Steinert J. Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders. Acta Psychiatr. Scand. 91:1995;40-43.
146. Redei E., Hilderbrand H., Aird F. Corticotropin release-inhibiting factor is encoded within prepro-TRH. Endocrinology. 136:1995;1813-1816.
147. Redei E., Hilderbrand H., Aird F. Corticotropin release-inhibiting factor is prepro-thyrotropin-releasing hormone (178-199). Endocrinology. 136:1995;3557-3563.
148. Regoli D., Boudon A., Fauchere J.L. Receptors and antagonists for substance P and related peptides. Pharmacol. Rev. 46:1994;551-599.
149. Reinscheid R.K., Nothacker H.P., Bourson A., Ardati A., Henningsen R.A., Bunzow J.R., Grandy D.K., Langen H., Monsma F.J. Jr., Civelli O. Orphanin FQ: a neuropeptide that activates an opioid like G protein-coupled receptor. Science. 270:1995;792-794.
150. Rickels K., Schweizer E., DeMartinis N., Mandos L., Mercer C. Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial. J. Clin. Psychopharmacol. 17:1997;272-277.
151. Roberts G.W., Woodhams P.L., Polak J.M., Crow T.J. Distribution of neuropeptides in the limbic system of the rat: the amygdaloid complex. Neuroscience. 7:1982;99-131.
152. Rodgers R.J., Blanchard D.C., Wong L.E., Blanchard R.J. Effects of scopolamine on antipredator defense reactions in wild and laboratory rats. Pharmacol. Biochem. Behav. 36:1990;575-583.
153. Rowe W., Viau V., Meaney M.J., Quirion R. Stimulation of CRH-mediated ACTH secretion by central administration of neurotensin: evidence for the participation of the paraventricular nucleus. J. Neuroendocrinol. 7:1995;109-117.
154. Rowe W.B., Nicot A., Sharma S., Gully D., Walker C.D., Rostene W.H., Meaney M.J., Quirion R. Central administration of the neurotensin receptor antagonist, SR48892, modulates diurnal and stress-related hypothalamic-pituitary-adrenal activity. Neuroendocrinology. 66:1997;75-85.
155. A receptor subtypes. Nature. 401:1999;796-800.
156. Russell J.M., Koran L.M., Rush J., Hirschfeld R.M., Harrison W., Friedman E.S., Davis S., Keller M. Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress. Anxiety. 13(1):2001;18-27.
157. Sarret P., Beaudet A., Vincent J.P., Mazella J. Regional and cellular distribution of low affinity neurotensin receptor mRNA in adult and developing mouse brain. J. Comp. Neurol. 394:1998;344-356.
158. Schopf J., Laurian S., Le P.K., Gaillard J.M. Intrinsic activity of the benzodiazepine antagonist Ro 15-1788 in man: an electrophysiological investigation. Pharmacopsychiatry. 17:1984;79-83.
159. Semenova G.P., Gurevich E.V., Kozlovskaia M.M., Gromova E.A. The role of the brain monoaminergic systems in the effects of tuftsin and its analog on animal emotional behavior. Fiziol. Z. SSSR. 75:1989;759-765.
160. Seredenin S.B., Semenova T.P., Kozlovskaia M.M., Medvinskaia N.I., Nezovibatko V.N. The characteristics of the anxiolytic action of tuftsin and its analog TP-7 on behavior and serotonin metabolism in the brain of rats with chronic deprivation of serotoninergic system activity. Eksp. Klin. Farmakol. 58:1995;3-6.
161. Seredenin S.B., Kozlovskaya M.M., Blednov Y.A., Semenova T.P., Kozlovskii I.I., CzabakGarbacz R., Nezavibatko V.N., Myasoedov N.F. The study of anxiolytic activity of tuftsin analogue in inbred mice with different types of emotional-stress reaction. Z. Vyss. Nervn. Deat. Pavlova. 48:1998;153-160.
162. 1b receptor antagonist. J. Pharmacol. Exp. Ther. 300:2002;1122-1130.
163. Sheehan D.V., Raj A.B., Sheehan K.H., Soto S. Is buspirone effective for panic disorder? J. Clin. Psychopharmacol. 10:1990;3-11.
164. Shepherd J.K., Rodgers R.J., Blanchard R.J., Magee L., Blanchard D.C. Ondansetron, gender, and antipredator defensive behavior. J. Psychopharmacol. 7:1993;72-81.
165. Siemion I.Z., Kluczyk A. Tuftsin: on the 30-year anniversary of Victor Najjar's discovery. Peptides. 20:1999;645-674.
166. Smith P.A., Moran T.D. The nociceptin receptor as a potential target in drug design. Drug News Perspect. 14:2001;335-345.
167. Solyom L., Solyom C., Ledwidge B. Fluoxetine in panic disorder. Can. J. Psychiatry. 36:1991;378-380.
168. Squires R.F., Benson D.I., Braestrup C., Coupet J., Klepner C.A., Myers V., Beer B. Some properties of brain specific benzodiazepine receptors: new evidence for multiple receptors. Pharmacol. Biochem. Behav. 10:1979;825-830.
169. Sramek J.J., Robinson R.E., Suri A., Cutler N.R. Efficacy trial of the 5-HT2, antagonist MDL 11,939 in patients with generalized anxiety disorder. J. Clin. Psychopharmacol. 15:1995;20-22.
170. Stahl C.E., Redei E., Wang Y., Borlongan C.V. Behavioral, hormonal and histological stress markers of anxiety-separation in postnatal rats are reduced by prepro-thyrotropin-releasing hormone 178-199. Neurosci. Lett. 321:2002;85-89.
171. Steinberg R., Alonso R., Griebel G., Bert L., Jung M., Oury-Donat F., Poncelet M., Gueudet C., Desvignes C., Le Fur G., Soubrie P. Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function. J. Pharmacol. Exp. Ther. 299:2001;449-458.
172. St. Pierre S., Quirion R., Regoli D., Gervais A., Lavigne F., Poirier A., Jolicoeur F., Barbeau A., Rioux F. Neurotensin, a multi-action peptide hormone. Union Med. Can. 109:1980;1447-1455.
173. Treves A. Vigilance and spatial cohesion among blue monkeys. Folia Primatol. (Basel). 70(5):1999;291-294.
174. Vaccari C., Lolait S.J., Ostrowski N.L. Comparative distribution of vasopressin V1b and oxytocin receptor messenger ribonucleic acids in brain. Endocrinology. 139:1998;5015-5033.
175. Vale W.W., Spiess J., Rivier C., Rivier J. Characterization of a 41 residue ovine hypothalamic peptide that stimulates the secretion of corticotropin and β-endorphin. Science. 213:1981;1394-1397.
176. Vale W.W., Rivier C., Brown M.R., Spiess J., Koob G., Swanson L., Bilezikjian L., Bloom F., Rivier J. Chemical and biological characterization of corticotropin-releasing factor. Recent Prog. Horm. Res. 39:1983;245-270.
177. Van Vliet I.M., Westenberg H.G.M., Den Boer J.A. Effects of the 5-HT1A receptor agonist flesinoxan in panic disorder. Psychopharmacology. 127:1996;174-180.
178. Walker N., Lepee-Lorgeoux I., Fournier J., Betancur C., Rostene W., Ferrara P., Caput D. Tissue distribution and cellular localization of the levocabastine-sensitive neurotensin receptor mRNA in adult rat brain. Brain Res., Mol. Brain Res. 57:1998;193-200.
179. Westenberg H.G.M. Developments in the drug treatment of panic disorder: what is the place of the selective serotonin reuptake inhibitors? J. Affect. Disord. 40:1996;85-93.
180. Westenberg H.G., Den Boer J.A. Selective monoamine uptake inhibitors and a serotonin antagonist in the treatment of panic disorder. Psychopharmacol. Bull. 25:1989;119-123.
181. Westenberg H.G.M., Den Boer J.A. Serotonin in anxiety related disorders. Vanhoutte P.M., Saxena P.R., Paoletti R., Brunello N., Jackson A.S. Serotonin, From Cell Biology to Pharmacology and Therapeutics. 1993;249-254 Kluwer Academic Publishers, Dordrecht.
182. A agonist, in the treatment of panic disorder. Clin. Neuropharmacol. 15:1992;60. (Suppl.).
183. Woods J.H., Winger G. Current benzodiazepine issues. Psychopharmacology. 118:1995;107-115.
184. Woods S.W., Charney D.S., Silver J.M., Krystal J.H., Heninger G.R. Behavioral, biochemical, and cardiovascular responses to the benzodiazepine receptor antagonist flumazenil in panic disorder. Psychiatry Res. 36:1991;115-127.
185. Young L.J., Toloczko D., Insel T.R. Localization of vasopressin (V1a) receptor binding and mRNA in the rhesus monkey brain. J. Neuroendocrinol. 11:1999;291-297.
186. Zohar J., Westenberg H.G.M. Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr. Scand. 101:2000;39-49.